On August 8, 2013, Gretchen Bowker, co-founder and COO of Pearl Pathways, will host a webinar on ComplianceOnline.com reviewing the similarities and differences in the regulatory paths and requirements for drugs, biologics and medical devices. It will discuss the...
In the last 5 years, big pharma has continued its move toward large molecules and biologics for drug development. Two recent studies from Withers & Rogers (a UK law firm specializing in IP) and KMR Group (a pharma consultancy) report on some of the trends among...
